FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

PRINCETON, N.J.--(BUSINESS WIRE) July 24, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news